EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China

Qiuwen Ye, Zhengrui Song, Tingdong Yu, Yong Li, Liang Ai, Guangjun Yang, Kun Su, Dong Chen, Wentao Zhao, Rong Ding, Yong Zha, Gang Li iD

Journal of Hepatocellular Carcinoma · 2025-08 · Volume 12 · 1905-1919

DOI: 10.2147/jhc.s532120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2025-08. Verfasst von Qiuwen Ye und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Unresectable hepatocellular carcinoma (uHCC) remains a major clinical challenge with limited effective therapeutic options. Triple therapy combining interventional treatments, donafenib, and anti-PD-1 monoclonal antibodies has shown promise in recent studies, but real-world data remain limited.

Objective

To evaluate the real-world efficacy and safety of triple therapy with interventional treatment, donafenib, and anti-PD-1 monoclonal antibodies in patients with uHCC.

Methods

This retrospective study included 89 patients with uHCC who received donafenib, anti-PD-1 monoclonal antibodies (tislelizumab or sintilimab), and interventional therapies (TACE and/or HAIC) between March 2022 and December 2023. Outcomes included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Efficacy was assessed using modified RECIST (mRECIST) criteria; prognostic factors were analyzed using Cox regression models.

Results

Among 89 patients, the ORR was 75.3% and the disease control rate was 100%. The median PFS was 18.5 months (95% CI: 15.0-NA); median OS was not reached after a median follow-up of 13.7 months. PFS rates at 6, 12, and 18 months were 87.6%, 72.4%, and 52.7%, and OS rates were 93.3%, 81.6%, and 72.4%, respectively. Conversion surgery was achieved in 15.7% of patients. Subgroup analysis indicated that ECOG PS 1, extrahepatic metastases, and high baseline AFP were associated with worse survival outcomes, while interventional modality did not significantly affect prognosis. Multivariate analysis confirmed ECOG PS 1 and extrahepatic metastases as independent predictors of shorter PFS, and ECOG PS 1 and elevated AFP as independent predictors of worse OS. Grade ≥3 treatment-related adverse events occurred in 30.3% of patients; no treatment-related deaths were reported.

Conclusion

The combination of interventional therapies, donafenib, and anti-PD-1 monoclonal antibodies demonstrated promising efficacy and manageable safety in uHCC, warranting further validation in prospective trials.

Schlagwörter

Stichwörter der Autor:innen

donafenibhepatocellular carcinomaimmune checkpoint inhibitorsinterventional therapiestyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China.
  • Department of Radiology, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China.
  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, People's Republic of China.
  • Department of Ultrasound Medicine, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China.
  • Department of Gastrointestinal Oncology, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China.
  • Department of Minimally Invasive Interventional Therapy, Yunnan Cancer Hospital, Kunming, Yunnan, People's Republic of China.

ORCID-Profile: Gang Li

Zitieren

APA

Ye, Q., Song, Z., Yu, T., Li, Y., Ai, L., Yang, G., Su, K., Chen, D., Zhao, W., Ding, R., Zha, Y., & Li, G. (2025). Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China. Journal of Hepatocellular Carcinoma, Volume 12, 1905-1919. https://doi.org/10.2147/jhc.s532120

Vancouver

Ye Q, Song Z, Yu T, Li Y, Ai L, Yang G, et al. Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China. Journal of Hepatocellular Carcinoma. 2025;Volume 12:1905-1919. doi:10.2147/jhc.s532120

BibTeX
@article{Ye2025,
  author = {Ye, Qiuwen and Song, Zhengrui and Yu, Tingdong and Li, Yong and Ai, Liang and Yang, Guangjun and Su, Kun and Chen, Dong and Zhao, Wentao and Ding, Rong and Zha, Yong and Li, Gang},
  title = {Triple Therapy with Interventional Treatment, Donafenib, and Anti-PD-1 Antibodies in Unresectable Hepatocellular Carcinoma: A Retrospective Real-World Study in China},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2025},
  volume = {Volume 12},
  pages = {1905--1919},
  doi = {10.2147/jhc.s532120}
}
Kostenlos starten →